Ophorst OJ - Search Results

1

Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice.

Ophorst OJ, Radosević K, Havenga MJ, Pau MG, Holterman L, Berkhout B, Goudsmit J, Tsuji M. Ophorst OJ, et al. Infect Immun. 2006 Jan;74(1):313-20. doi: 10.1128/IAI.74.1.313-320.2006. Infect Immun. 2006. PMID: 16368986 Free PMC article.

2

Expression and immunogenicity of the Plasmodium falciparum circumsporozoite protein: the role of GPI signal sequence.

Ophorst OJ, Radosević K, Ouwehand K, van Beem W, Mintardjo R, Sijtsma J, Kaspers J, Companjen A, Holterman L, Goudsmit J, Havenga MJ. Ophorst OJ, et al. Vaccine. 2007 Feb 9;25(8):1426-36. doi: 10.1016/j.vaccine.2006.10.050. Epub 2006 Nov 7. Vaccine. 2007. PMID: 17161889

3

Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant.

Ophorst OJ, Radosević K, Klap JM, Sijtsma J, Gillissen G, Mintardjo R, van Ooij MJ, Holterman L, Companjen A, Goudsmit J, Havenga MJ. Ophorst OJ, et al. Vaccine. 2007 Aug 29;25(35):6501-10. doi: 10.1016/j.vaccine.2007.06.019. Epub 2007 Jun 29. Vaccine. 2007. PMID: 17646036

4

An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity.

Ophorst OJ, Kostense S, Goudsmit J, De Swart RL, Verhaagh S, Zakhartchouk A, Van Meijer M, Sprangers M, Van Amerongen G, Yüksel S, Osterhaus AD, Havenga MJ. Ophorst OJ, et al. Vaccine. 2004 Aug 13;22(23-24):3035-44. doi: 10.1016/j.vaccine.2004.02.011. Vaccine. 2004. PMID: 15297053

5

Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.

Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Béthune MP, Kostense S, Penders G, Helmus N, Koudstaal W, Cecchini M, Wetterwald A, Sprangers M, Lemckert A, Ophorst O, Koel B, van Meerendonk M, Quax P, Panitti L, Grimbergen J, Bout A, Goudsmit J, Havenga M. Vogels R, et al. J Virol. 2003 Aug;77(15):8263-71. doi: 10.1128/jvi.77.15.8263-8271.2003. J Virol. 2003. PMID: 12857895 Free PMC article.

6

Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease.

Havenga MJ, Lemckert AA, Ophorst OJ, van Meijer M, Germeraad WT, Grimbergen J, van Den Doel MA, Vogels R, van Deutekom J, Janson AA, de Bruijn JD, Uytdehaag F, Quax PH, Logtenberg T, Mehtali M, Bout A. Havenga MJ, et al. Among authors: ophorst oj. J Virol. 2002 May;76(9):4612-20. doi: 10.1128/jvi.76.9.4612-4620.2002. J Virol. 2002. PMID: 11932426 Free PMC article.

7

Human adenovirus type 35 vector for gene therapy of brain cancer: improved transduction and bypass of pre-existing anti-vector immunity in cancer patients.

Brouwer E, Havenga MJ, Ophorst O, de Leeuw B, Gijsbers L, Gillissen G, Hoeben RC, ter Horst M, Nanda D, Dirven C, Avezaat CJ, Goudsmit J, Sillevis Smitt P. Brouwer E, et al. Cancer Gene Ther. 2007 Feb;14(2):211-9. doi: 10.1038/sj.cgt.7701010. Epub 2006 Nov 3. Cancer Gene Ther. 2007. PMID: 17082793

8

Intradermal delivery of adenoviral type-35 vectors leads to high efficiency transduction of mature, CD8+ T cell-stimulating skin-emigrated dendritic cells.

de Gruijl TD, Ophorst OJ, Goudsmit J, Verhaagh S, Lougheed SM, Radosevic K, Havenga MJ, Scheper RJ. de Gruijl TD, et al. Among authors: ophorst oj. J Immunol. 2006 Aug 15;177(4):2208-15. doi: 10.4049/jimmunol.177.4.2208. J Immunol. 2006. PMID: 16887980

9

Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice.

Shott JP, McGrath SM, Pau MG, Custers JH, Ophorst O, Demoitié MA, Dubois MC, Komisar J, Cobb M, Kester KE, Dubois P, Cohen J, Goudsmit J, Heppner DG, Stewart VA. Shott JP, et al. Vaccine. 2008 Jun 2;26(23):2818-23. doi: 10.1016/j.vaccine.2008.03.080. Epub 2008 Apr 16. Vaccine. 2008. PMID: 18455276

10

Parents' attitude toward multiple vaccinations at a single visit with alternative delivery methods.

Kaaijk P, Kleijne DE, Knol MJ, Harmsen IA, Ophorst OJ, Rots NY. Kaaijk P, et al. Among authors: ophorst oj. Hum Vaccin Immunother. 2014;10(8):2483-9. doi: 10.4161/hv.29361. Hum Vaccin Immunother. 2014. PMID: 25424960 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

13 results

Search Page